차바이오텍

085660KOSDAQ기초 의약물질 제조업

43.3 / 100

Reference Date: 2026-06-10

Financial Score14.0 / 40

News Sentiment16.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Plunged 28.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Cha BioTech primarily operates in umbilical cord blood storage, stem cell research, cell therapy development, anti-aging services, and consulting. The company also engages in pharmaceuticals, global CDMO, and international healthcare network expansion through its major subsidiaries. In 2024, revenue was distributed as 61.06% in medical services, 10.43% in product sales, and 28.51% in other services.

Number of Employees

354people

Average Salary

51.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

1.33Industry Average 1.744.0Point

In line with industry avg

ROE

-19.32Industry Average -6.033.5Point

3.2x industry avg (excellent)

Debt Ratio

51.30Industry Average 6.620.0Point

7.7x industry avg (risky)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼252.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.4% (declining, 3yr)

Detailed News Sentiment

14 totalPositive 7Neutral 7Negative 0Average Sentiment Score 65.4

Neutral
차병원·차바이오그룹, 임원·경력직 공채…15일까지 접수
차바이오텍 관련 채용 소식은 직접적인 영향이 적어 중립적 평가.
Positive
[단독] 차바이오텍, 고정재 교수 고문 편입…난임 사업 재조명
차바이오텍의 고정재 교수 영입으로 여성의학 및 난임 분야의 핵심 사업이 재조명되어 긍정적인 시장 반응 예상.
Positive
차바이오텍 자회사 차헬스케어, 시니어 특화 헬스케어 모델 구축
차바이오텍 자회사 차헬스케어의 시니어 특화 커넥티드 헬스케어 모델 구축 소식으로 인해 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 11,610Won52-week high 23,85052-week low 10,120

1-month return0.0Point

1m -28.20% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]사업보고서 (2025.12)2026-06-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-22
Neutral[기재정정]주식매수선택권부여에관한신고2026-05-18
Neutral분기보고서 (2026.03)2026-05-15